68Ga-DOTATOC
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Conditions
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Trial Timeline
Feb 22, 2024 → Nov 1, 2025
NCT ID
NCT06091748About 68Ga-DOTATOC
68Ga-DOTATOC is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Advanced Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06091748. Target conditions include Advanced Gastroenteropancreatic Neuroendocrine Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Gastroenteropancreatic Neuroendocrine Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06091748 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Gastroenteropancreatic Neuroendocrine Tumor